Friends of Cancer Research (Friends) is proud to join our many partner organizations in announcing the launch of the Lung Cancer Master Protocol (Lung-MAP) clinical trial. Lung-MAP is the product of years of collaboration with government, research institutions, patient advocacy groups, and industry, and it is our hope that it will provide a model for…
Chair & Founder Ellen Sigal Participates in Inaugural Roundtable Executive Director Jeff Allen Testifies Before House Energy and Commerce Committee On May 6, 2014, Friends Chair & Founder, Dr. Ellen Sigal joined NIH Director Francis Collins, FDA’s Dr. Janet Woodcock, as a participant on the same committees’ kickoff event for the “21st Center Cures…
Washington, DC – Friends of Cancer Research (Friends), a Washington, DC-based think tank and advocacy organization, announced the appointment of Joel S. Marcus, Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. /Alexandria Venture Investments, to its Board of Directors. In addition to his work in life science real estate, Mr. Marcus…
2013 Breakthrough Therapies Designation Year-End Update Designations Granted by the FDA: 37 Requests Denied by the FDA: 70 Designations Announced Publicly by Companies: 28 Cancer: 12 Hepatitis C: 4 Cystic Fibrosis: 2 Autoimmune Disorders: 2 (Lambert Eaton Myasthenic Syndrome) (Sporadic inclusion body myositis) Heart Disease: 1 Malaria: 1 Antidote for Factor…
WASHINGTON, DC (December 9, 2013) – Today, Friends of Cancer Research is excited to announce the launch of the online forum “Engaging Innovation.” Leaders from regulation, research, drug development, treatment, and advocacy will share insights and innovations in an ongoing dialogue about the most critical issues in the fight against cancer. Our inaugural entry is an interview…
APRIL 30, 2013 – WASHINGTON, DC — Friends of Cancer Research (Friends) is proud to honor Ms. Sherry Lansing with the inaugural Ellen V. Sigal Advocacy Leadership Award. Friends is continually cited for changing the landscape of how drugs are researched, evaluated and approved. The truly unique and groundbreaking scientific partnerships, as well as bipartisan…
Washington, D.C. (July 9, 2012) The signing of Food and Drug Administration Safety and Innovation Act (FDASIA) into law today represents the culmination of a year of true collaboration for the best interests of patients. The open, inclusive and constructive dialogue during the formative stages of the fifth Prescription Drug User Fee Act (PDUFA) reauthorization…
The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens…
Bill Would Expedite FDA Approval and Increase Clinical Trial Flexibility of Drugs and Treatments That Show Dramatic Early Responses – Washington, DC – Senators Michael Bennet (D-CO), Orrin Hatch (R-UT) and Richard Burr (R-NC) today introduced a bipartisan bill to help bring breakthrough drugs and treatments to patients who need them more quickly. The Advancing…
The SSO Recognized Paulsen for Her Leadership of the Entertainment Industry Foundation, Including Her Efforts in the Creation of the “Stand Up To Cancer” Initiative – Los Angeles, CA – March 23, 2012 – The Society of Surgical Oncology (SSO) and its James Ewing Foundation recognized the efforts of Stand Up to Cancer’s co-founder Lisa…
